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To the Editor:
We reported the case of an ana-
plastic lymphoma kinase  (ALK)-positive 
patient with disseminated intravascular 
coagulation (DIC) who experienced 
a dramatic response to crizotinib.1 In 
addition to reporting the efficacy of 
crizotinib to the case in a critical con-
dition such as DIC, we would like to 
add one more important finding regard-
ing this case. The patient received four 
regimens of chemotherapy before the 
administration of crizotinib, and the 
fourth regimen, which was described 
as an investigational drug in the text, 
was in fact CH5424802 (alectinib).2 
CH5424802 achieved a partial response 
(best percentage change in target 
lesions from baseline: −78%), and 
the duration of CH5424802 was 10.5 
months, followed by the rapid progres-
sion of multiple liver metastases and 
the development of DIC. After the dra-
matic improvement of DIC achieved 
with crizotinib, a biopsy of the meta-
static lesion in the liver was performed, 
the specimen of which demonstrated 
amplification of the met proto-oncogene 
(MET) gene, as shown in the Figure 1, 
although no resistant mutations in the 
ALK gene and no mutations of epider-
mal growth factor receptor and Kirsten 
rat sarcoma viral oncogene homolog 
(KRAS) were observed. In addition, a 
critical point is that crizotinib, which 
was originally developed as an inhibitor 
of the MET gene,3 was effective in this 
patient as shown in the original article. 
Based on these results, the MET gene 
was assumed to act as a driver of resis-
tance for CH5424802, which has not 
been previously reported. The duration 
of crizotinib therapy was five months, 
and the patient died approximately 
7 months after the start of crizotinib.
With regard to the mechanism 
underlying the development of acquired 
resistance to ALK inhibitors, although 
resistance mechanisms, such as muta-
tions of epidermal growth factor recep-
tor and KRAS and amplification of the 
v-kit Hardy-Zuckerman 4 feline sar-
coma viral oncogene homolog (KIT) 
gene, as well as secondary mutations 
of the ALK gene,4,5 have been reported, 
no reports have indicated a resistance 
mechanism involving amplification of 
the MET gene. In vitro and in vivo anal-
yses are warranted to confirm this novel 
resistance mechanism.
In conclusion, we would like 
thoracic oncologists to know this criti-
cal information because the possible 
mechanism of acquired resistance to 
CH5424802 via the amplification of 
the MET gene is novel, and crizotinib, 
which is a dual inhibitor of ALK and 
MET, may be used to overcome this 
possible resistance mechanism. In the 
near future, a prospective study is war-
ranted to investigate the significance 
of specific treatment strategies accord-
ing to the resistance mechanism in 
ALK-positive patients with acquired 
resistance to ALK inhibitors, such as 
CH5424802. In such a study, a second 
biopsy should be routinely performed 
after the acquisition of resistance to the 
ALK inhibitors to examine amplifica-
tion of the MET gene as well as other 
resistance mechanisms, if possible.
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FIGURE 1.  A fluorescence in situ hybridization assay showing the amplification of 
the MET gene. Blue: 4′,6-diamidino-2-phenylindole (DAPI); red: met proto-onco-
gene (MET); green: 7q11.21.
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Jakobsen et al.1 on the Danish Lung 
Cancer registry.
The authors describe the estab-
lishment of a national quality man-
agement system stemming from the 
development of national guidelines, 
the creation of a high-quality inte-
grated data system, frequent reports, 
and a process of audit evaluation and 
scrutiny that engages both stakeholder 
clinicians and institutions and regional 
and national health care authorities. 
Within the space of a decade, statisti-
cally and clinically important improve-
ments are demonstrated in 1-, 2-, and 
5-year survival, in addition to reduced 
waiting time, enhanced clinical and 
pathological staging concordance and 
reduction in regional variation in clini-
cal outcomes.
During this timeframe there seems 
a substantial increase in active cancer 
treatment including surgical resection, 
chemotherapy, and radiotherapy. The rate 
of potentially curative therapy, however, 
including resection rate (15%–17%) and 
rate of combined chemo-radiotherapy 
(with likely curative intent, 10%–14%) 
remained unchanged. Improved subject 
selection, characterization, and treatment 
selection are likely to improve outcomes 
in those receiving potentially curative 
treatment; however, equally appeal-
ing, yet undescribed, is the possibility 
of enhanced survival in those receiving 
treatment with noncurative intent.
Clearly the success of the initia-
tive rests on a sophisticated, informed, 
and interactive relationship between 
government, health authorities, and 
clinicians. Drivers to engagement are 
likely to include political demand and 
an important administrative recognition 
of the capability of the Danish Lung 
Cancer registry to capture necessary 
core clinical data as a mechanism to 
enable feedback and closure of the qual-
ity cycle.2 The report of similar trends 
by the national Lung Cancer Audit in 
the United Kingdom may support these 
findings.3
The pursuit of quality and safety 
in health care demands definition of 
markers that describe the structure, 
quality, and outcomes of health care 
processes.4 Although governments and 
health care providers strive to develop 
 disease-relevant and epidemiologically 
robust measures of quality there remains 
a major gap, with relatively few exam-
ples of nationwide,  population-based 
systems established for such data collec-
tion.5 The peer-reviewed publication of 
outcomes attributable to clinical quality 
registry activity does much to promote 
registry science and demonstrates a 
potentially powerful role in advancing 
safety and quality in health care out-
comes. The Danish Lung Cancer Group 
and Danish Government have provided 
significant leadership and demonstrate 
powerful survival impact through the use 
of a clinical quality registry. Our con-
stituents may well ask, “Why aren’t we 
following?”
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To the Editor:
Improving outcomes such as diag-
nosis, staging, and survival in lung 
cancer is the objective of all stake-
holders in what remains a disease 
that is largely treatment resistant. Our 
interest is usually drawn to announce-
ments of development and innovation 
in the fields of diagnostics and thera-
peutics. Few perhaps might anticipate 
that the use of available data may have 
the potential to result in credible and 
substantial improvements in diagno-
sis and staging quality, care provi-
sion, and both short- and longer-term 
survival. This, however, is precisely 
what is offered in the recent report by 
